Compare SURG & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SURG | PMN |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Advertising | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 131.5M |
| IPO Year | 2019 | 2022 |
| Metric | SURG | PMN |
|---|---|---|
| Price | $0.16 | $13.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $42.67 |
| AVG Volume (30 Days) | ★ 8.0M | 33.5K |
| Earning Date | 04-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.69 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $56,962,920.00 | N/A |
| Revenue This Year | $136.77 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.15 | $0.29 |
| 52 Week High | $3.14 | $27.40 |
| Indicator | SURG | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 37.89 | 46.73 |
| Support Level | $0.15 | $12.89 |
| Resistance Level | $0.94 | $14.77 |
| Average True Range (ATR) | 0.02 | 1.17 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 17.45 | 33.23 |
Surgepays Inc is a wireless and point of sale technology company focused on serving underserved and value-conscious consumers through a combination of retail distribution and digital acquisition channels. It provides mobile connectivity, financial technology services, and transaction processing solutions through an integrated platform that combines wireless services with point of sale software and retail distribution. It enables in-store and online activation of wireless services, prepaid top-ups, and financial transactions, allowing consumers to access essential services in both local and digital environments. Its segments are wireless services or MVNO Telecommunications, platform services or MVNE Enablement Platform (HERO), and wholesale enablement or Comprehensive Platform Services.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.